- Home
- S vs ACLX Comparison
S vs ACLX Comparison
Compare S & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$13.30
HOLD
Current Price
$114.77
Company Overview
Basic Information| Metric | S | ACLX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | S | ACLX |
|---|---|---|
| Price | $13.30 | $114.77 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 32 | 15 |
| Target Price | $19.50 | ★ $115.85 |
| AVG Volume (30 Days) | ★ 7.8M | 1.2M |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,001,278,000.00 | $22,286,000.00 |
| Revenue This Year | $22.84 | $397.53 |
| Revenue Next Year | $17.32 | $123.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 21.89 | N/A |
| 52 Week Low | $12.15 | $47.86 |
| 52 Week High | $21.40 | $114.91 |
Technical Indicators
Market Signals| Indicator | S | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.55 | 81.46 |
| Support Level | $12.33 | $66.06 |
| Resistance Level | $15.28 | $114.86 |
| Average True Range (ATR) | 0.65 | 0.28 |
| MACD | -0.13 | -1.54 |
| Stochastic Oscillator | 42.25 | 75.78 |
Price Performance
Historical Comparison S
ACLX
About S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.